Rogel Cancer Center: University of Michigan
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1991-01-01
- Employees
- -
- Market Cap
- -
A Phase II Study for p16+ Oropharyngeal Cancer PerSonalized De-escalation Treatment at University of MIchigan (CuSToMIze)
Phase 2
Recruiting
- Conditions
- Squamous Cell Carcinoma of the OropharynxOropharyngeal Cancer
- Interventions
- Combination Product: ChemoradiationProcedure: SurgeryOther: ObservationRadiation: Post-operative radiation
- First Posted Date
- 2023-06-08
- Last Posted Date
- 2025-06-03
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Target Recruit Count
- 150
- Registration Number
- NCT05894083
- Locations
- 🇺🇸
University of Michigan Rogel Cancer Center, Ann Arbor, Michigan, United States
Cardiac Rehabilitation to Improve Breast Cancer Outcomes
Not Applicable
Terminated
- Conditions
- Cardiovascular DiseasesBreast Cancer
- Interventions
- Other: Cardiac Rehab
- First Posted Date
- 2023-05-22
- Last Posted Date
- 2025-04-08
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Target Recruit Count
- 4
- Registration Number
- NCT05867667
- Locations
- 🇺🇸
University of Michigan Rogel Cancer Center, Ann Arbor, Michigan, United States
Parametric Response Mapping (PRM) for the Detection of Chronic Lung Injury in Hematopoietic Cell Transplant Recipients
Recruiting
- Conditions
- Graft Versus Host DiseaseHematopoietic Cell TransplantationChronic Lung Disease
- First Posted Date
- 2023-05-19
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Target Recruit Count
- 375
- Registration Number
- NCT05866302
- Locations
- 🇺🇸
Stanford Hospital, Stanford, California, United States
🇺🇸Emory University, Atlanta, Georgia, United States
🇺🇸Dana Farber, Boston, Massachusetts, United States
A Proof of Concept Pilot Study of the Addition of Venetoclax to Standard Remission Induction Chemotherapy Fludarabine or Cladrabine, Cytarabine, and Granulocyte Colony Stimulating Factor (G-CSF) (FLAG or CLAG) for Frontline Therapy of Secondary Acute Myeloid Leukemia
Phase 2
Recruiting
- Conditions
- Secondary Acute Myeloid Leukemia
- Interventions
- Drug: FLAG or CLAG Protocol
- First Posted Date
- 2023-03-23
- Last Posted Date
- 2025-06-25
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Target Recruit Count
- 20
- Registration Number
- NCT05780879
- Locations
- 🇺🇸
University of Michigan Rogel Cancer Center, Ann Arbor, Michigan, United States
Optimizing Active Surveillance in Low-Risk Prostate Cancer: a Pilot Study
Not Applicable
Completed
- Conditions
- Prostate Cancer
- Interventions
- Behavioral: MUSIC websiteBehavioral: web-based tool (MAP- Management of Active surveillance in Prostate Cancer)
- First Posted Date
- 2023-03-10
- Last Posted Date
- 2024-06-07
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Target Recruit Count
- 40
- Registration Number
- NCT05764005
- Locations
- 🇺🇸
University of Michigan Rogel Cancer Center, Ann Arbor, Michigan, United States
Feasibility and Acceptability of Brief, Telehealth Cognitive Compensatory Training for Pediatric Cancer Patients
Not Applicable
Active, not recruiting
- Conditions
- Pediatric Cancer
- Interventions
- Other: Cognitive Compensatory Training
- First Posted Date
- 2023-01-30
- Last Posted Date
- 2024-08-20
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Target Recruit Count
- 26
- Registration Number
- NCT05704790
- Locations
- 🇺🇸
University of Michigan, Ann Arbor, Michigan, United States
Phase IV Multi-arm Study of CDK4/6 Pharmacokinetics in Healthy Volunteers With Known CYP3A4*22 Genotype
Phase 4
Withdrawn
- Conditions
- CYP3A4*22
- Interventions
- First Posted Date
- 2023-01-20
- Last Posted Date
- 2024-02-02
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Registration Number
- NCT05691400
Metastatic Leiomyosarcoma Biomarker Protocol
Recruiting
- Conditions
- Leiomyosarcoma
- Interventions
- Other: Plasma Collection
- First Posted Date
- 2022-12-16
- Last Posted Date
- 2025-07-02
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Target Recruit Count
- 200
- Registration Number
- NCT05653388
- Locations
- 🇺🇸
Sarcoma Oncology Research Center, Santa Monica, California, United States
🇺🇸Dana- Farber, Boston, Massachusetts, United States
🇺🇸University of Michigan Cancer Center, Ann Arbor, Michigan, United States
Evaluating a Pharmacogenetic Testing Panel in Patients Suspected to be at Increased Risk for Pharmacogenetics-related AEs While Receiving Fluoropyrimidine or Irinotecan Therapy
Not Applicable
Completed
- Conditions
- Cancer
- Interventions
- Genetic: DPYD or UGT1A1 variants
- First Posted Date
- 2022-10-17
- Last Posted Date
- 2025-05-11
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Target Recruit Count
- 96
- Registration Number
- NCT05583422
- Locations
- 🇺🇸
University of Michigan Rogel Cancer Center, Ann Arbor, Michigan, United States
CLEAR Care Companion Application
Not Applicable
Completed
- Conditions
- Bladder CancerRadical Cystectomy
- Interventions
- Behavioral: CLEAR Care Companion (CC) application
- First Posted Date
- 2022-10-13
- Last Posted Date
- 2025-01-08
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Target Recruit Count
- 28
- Registration Number
- NCT05578898
- Locations
- 🇺🇸
University of Michigan Rogel Cancer Center, Ann Arbor, Michigan, United States